VCEL - NASDAQ
Vericel Corporation
$34.74
+2.7%Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotVericel Corporation Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Minimal operating profit suggests high operating costs or pricing challenges. Scalability is concerning.
Net Profit Margin
Moderate profitability with room for improvement. Monitor interest expenses and tax efficiency.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Vericel Corporation Income Statement
VCEL • NASDAQ
| Vericel Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Jun 2010 | Jun 2009 | Jun 2008 | Jun 2007 | Jun 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
276.3M | 237.2M | 197.5M | 164.4M | 156.2M | 124.2M | 117.9M | 90.9M | 63.9M | 54.4M | 51.2M | 28.8M | 19K | 21K | 18K | 89K | 182K | 522K | 685K | 863K | |
GROSS PROFIT | ||||||||||||||||||||
(70.7M) | (65.1M) | (61.9M) | (54.6M) | (50.2M) | (40M) | (37.6M) | (32.2M) | (30.4M) | (28.3M) | (26.5M) | (17.3M) | (4K) | (6K) | (4K) | (34K) | (112K) | (56K) | (29K) | (11K) | |
205.6M | 172.1M | 135.6M | 109.8M | 106M | 84.2M | 80.3M | 58.7M | 33.6M | 26.1M | 24.7M | 11.5M | 15K | 15K | 14K | 55K | 70K | 466K | 656K | 852K | |
OPERATING INCOME | ||||||||||||||||||||
(194.6M) | (167.6M) | (142M) | (126.8M) | (113.9M) | (81.9M) | (91.5M) | (62.6M) | (48.6M) | (42.7M) | (41.4M) | (35M) | (21M) | (33.8M) | (29.1M) | (17.9M) | (16.2M) | (21.7M) | (20.1M) | (18.6M) | |
(167M) | (142.8M) | (121M) | (106.9M) | (97.6M) | (68.8M) | (61.1M) | (49M) | (35.6M) | (27.4M) | (22.5M) | (13.8M) | (5.9M) | (7.8M) | (7.7M) | (5.2M) | (5M) | (6.4M) | (8.7M) | (9.1M) | |
(27.6M) | (24.8M) | (21M) | (19.9M) | (16.3M) | (13M) | (30.4M) | (13.6M) | (12.9M) | (15.3M) | (18.9M) | (21.3M) | (15.1M) | (26M) | (21.3M) | (12.7M) | (11.3M) | (15.2M) | (11.4M) | (9.5M) | |
11M | 4.5M | -6.5M | -17.1M | -7.9M | 2.4M | -11.3M | -3.9M | -15M | -19.2M | -16.7M | -23.5M | -21M | -33.8M | -29M | -17.8M | -16.2M | -21.2M | -19.5M | -17.7M | |
PRE-TAX INCOME | ||||||||||||||||||||
(1.6M) | (614K) | (600K) | (366K) | (4K) | (6K) | (8K) | (1.7M) | (1.1M) | (314K) | (9K) | (6K) | (11K) | (12K) | (10K) | (40K) | (73K) | (73K) | (84K) | (0.0) | |
5.5M | 5.8M | 4M | 975K | 220K | 685K | 1.6M | -835K | -1.1M | -306K | 27K | 18K | 5K | 38K | 43K | 75K | 75K | 223K | 1.1M | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -31K | -92K | -10K | (47K) | -2K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
6.3M | 6M | 4.1M | 1.1M | 272K | 672K | 1.6M | -4.2M | -2.3M | -321K | 331K | 3.6M | 5.3M | 4.3M | 9.4M | -20.4M | 1.9M | 223K | 1.1M | 1.9M | |
17.4M | 10.5M | -2.4M | -16M | -7.6M | 3M | -9.7M | -8.1M | -17.3M | -19.6M | -16.3M | -19.9M | -15.6M | -29.5M | -19.7M | -17.7M | -15.9M | -20.1M | -16.5M | -11.8M | |
NET INCOME | ||||||||||||||||||||
(859K) | (148K) | (814K) | (721K) | -111K | (180K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -18.7M | -115K | -296K | -1.1M | -1.8M | -1.3M | |
16.5M | 10.4M | -3.2M | -16.7M | -7.5M | 2.9M | -9.7M | -8.1M | -17.3M | -19.6M | -16.3M | -19.9M | -15.6M | -29.5M | -19.7M | -17.7M | -15.9M | -20.1M | -17.6M | -16.5M |
SEC Filings
VCEL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 18, 2026 | May 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 01, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 19, 2026 | April 29, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 13, 2026 | January 13, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 |
Related Guides
Continue your VCEL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.